Evommune, Inc. cotiza a 5.88 USD y tiene una capitalización bursátil de $213M. En los últimos 12 meses ha facturado $10M con un margen de flujo de caja libre del -589.8%. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. The company develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products i…
| Periodo | 2026-11 | 2026-08 | 2026-03 | 2025-12 |
|---|---|---|---|---|
| Real | — | $-0.89 | $-1.43 | $-8.07 |
| Estimado | $-0.83 | $-0.67 | $-0.84 | $-11.35 |
| Sorpresa | — | -32.8% | -70.2% | +28.9% |
| Métrica | EVMN | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | -623.6% | -38.6% | -585.0% |
| Net Margin | -529.8% | -33.6% | -496.2% |
| FCF Margin | -589.8% | -13.9% | -576.0% |
| ROE | -33.5% | -40.4% | +6.9% |
| ROA | -30.6% | -32.0% | +1.4% |
| Current Ratio | 8.57 | 2.84 | +5.73 |
| Debt / Equity | — | 0.28 | — |